Clinical trial
Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC
NCT07786428
Study timeline
Study start (estimated)2026-10-01Date precision: day
Registry last updated2026-08-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Triple-Negative Breast Cancer (TNBC)unresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
CarboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
University of Texas Southwestern Medical Centerlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07786428 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.